

1 **Draft Minutes**
2 **Meeting of the Toxicology Subcommittee**
3 **of the Scientific Advisory Committee**
4 **Department of Forensic Science**
5 **April 20, 2026**
6

7 **Subcommittee Members Present**

8 Randall E. Beaty
9 Marc A. LeBeau, Ph.D., *Chair*
10 Richard P. Meyers
11

12 **Staff Members Present**

13 David A. Barron, Ph.D., Deputy Director
14 James Hutchings, Ph.D.
15 Linda C. Jackson, Director
16 Amy Jenkins, Chief Deputy Director
17 David Koppenhaver, Eastern Laboratory Director
18 Tiffany Leusby, Forensic Scientist Senior
19 Alka B. Lohmann, Director of Technical Services
20 Kevin Patrick, Western Laboratory Director
21 David Siecker, Communications and Executive Support Specialist
22 Farryl Sorokin, Secretary to the Scientific Advisory Committee
23 Rebecca Wagner, Ph.D., Chemistry Research Section Supervisor
24

25 **Call to Order by Subcommittee Chair**

26 With a quorum of the Subcommittee present, Chair LeBeau called the meeting of the Toxicology
27 Subcommittee (“Subcommittee”) to order at 1:01 p.m.
28

29 **Adoption of Agenda**

30 Chair LeBeau advised that the first order of business was the adoption of the draft agenda for the
31 meeting and noted that the agenda was previously shared with the Subcommittee members by Ms.
32 Sorokin. Mr. Meyers made a motion to adopt the agenda, which was seconded and passed by
33 unanimous vote of the Subcommittee.
34

35 **Adoption of Draft Minutes from the October 7, 2025 Subcommittee Meeting**

36 Chair LeBeau noted that the draft minutes from the October 7, 2025 meeting of the Subcommittee
37 were previously shared and asked if there were any proposed changes. Being none, Chair LeBeau
38 asked for a motion to approve the minutes. Mr. Beaty made a motion that the minutes be approved,
39 which was seconded and adopted by unanimous vote.
40

41 **Discussion of Validation Summaries**

42 In advance of the meeting, the members of the Subcommittee were provided with two validation
43 summaries: (1) *Addition of Novel Psychoactive Substances to the Amphetamines, Phentermine,*
44 *and Designer Stimulants Quantitation and Confirmation by LCMSMS Method* and (2) *Qualitative*
45 *Addition of Seven Novel Benzodiazepines to the Benzodiazepines, Zolpidem, Zopiclone and*
46 *Zaleplon Quantitation and Confirmation by LCMSMS Method.*

47
48 Dr. Wagner provided an overview of the *Addition of Novel Psychoactive Substances to the*
49 *Amphetamines, Phentermine, and Designer Stimulants Quantitation and Confirmation by*
50 *LCMSMS Method*. Following her presentation, a question was raised seeking clarification about
51 the different types of blood samples that were used in the study.

52
53 Dr. Wagner provided an overview of *Qualitative Addition of Seven Novel Benzodiazepines to the*
54 *Benzodiazepines, Zolpidem, Zopiclone and Zaleplon Quantitation and Confirmation by LCMSMS*
55 *Method*. Following her presentation, questions arose and conversations ensued about the
56 variability of different drug responses.

57
58 Dr. Wagner presented on the Base Screen Method Development and explained they are working
59 on evaluating a base screen method for a unified approach to establish the limits of detection. A
60 more formal update will be presented at the next meeting of the Subcommittee.

61
62 After the discussion period, Chair LeBeau asked for a motion to close the discussion of *Addition*
63 *of Novel Psychoactive Substances to the Amphetamines, Phentermine, and Designer Stimulants*
64 *Quantitation and Confirmation by LCMSMS Method*. Mr. Meyers made a motion to close the
65 discussion, which was seconded and passed by unanimous vote of the Subcommittee.

66
67 Chair LeBeau then asked for a motion to close the discussion of *Qualitative Addition of Seven*
68 *Novel Benzodiazepines to the Benzodiazepines, Zolpidem, Zopiclone and Zaleplon Quantitation*
69 *and Confirmation by LCMSMS Method*. Mr. Beaty made a motion to close the discussion, which
70 was seconded and passed by unanimous vote of the Subcommittee.

71
72 **Public Comment**

73 An opportunity for public comment was provided. No members of the public were present to
74 provide comment.

75
76 **Adjournment**

77 Chair LeBeau asked for a motion to adjourn the meeting. Mr. Meyers made a motion to adjourn
78 the meeting, which was seconded and passed by unanimous vote of the Subcommittee. The
79 meeting adjourned at 1:21 p.m.